Findings

What do systematic reviews say?

4,703 questions · 15,007 findings · 1,416 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,881 · 19.2%GRADE not reported 1,551 · 10.3%Very low 3,111 · 20.7%Low 3,881 · 25.9%Moderate 2,669 · 17.8%High 914 · 6.1%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Propionyl‐L‐carnitine vs placebo

Change in ulcer size · individuals with sickle cell disease and a leg ulcer

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 15 participants
Very low

Propionyl‐L‐carnitine vs placebo

Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propionyl‐L‐carnitine vs placebo

Quality of life ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Isoxsuprine vs placebo

Time to ulcer closure ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propionyl‐L‐carnitine vs placebo

Amputation ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propionyl‐L‐carnitine vs placebo

Adverse events ‐ not measured · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RGD peptide matrix vs placebo

Complete closureUlcer area was determined by computerized planimetry · individuals with sickle cell disease and a leg ulcer

It is very uncertain whether RGD peptide matrix changes complete closureUlcer area was determined by computerized planimetry compared with placebo (very low certainty).

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
RR 0.4 [0.15, 1.04]
1 study · 55 participants
Very low

RGD peptide matrix vs placebo

Time to ulcer closure ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RGD peptide matrix vs placebo

Change in size ulcers healed ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RGD peptide matrix vs placebo

Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RGD peptide matrix vs placebo

Quality of life ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RGD peptide matrix vs placebo

Amputation ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RGD peptide matrix vs placebo

Adverse events · individuals with sickle cell disease and a leg ulcer

It is very uncertain whether RGD peptide matrix changes adverse events compared with placebo (very low certainty).

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
RR 0.76 [0.5, 1.17]
1 study · 55 participants
Very low

Isoxsuprine vs placebo

Change in ulcer size · individuals with sickle cell disease and a leg ulcer

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Very low

Isoxsuprine vs placebo

Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Isoxsuprine vs placebo

Quality of life ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Isoxsuprine vs placebo

Amputation ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Isoxsuprine vs placebo

Adverse events ‐ not reported · individuals with sickle cell disease and a leg ulcer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Paracetamol (single administration, any dose) vs placebo

Adequate pain relief as reported by women · women with perineal pain following childbirth

Paracetamol (single administration, any dose) may leads to higher adequate pain relief as reported by women compared with placebo (low certainty).

1 finding from 1 review

Paracetamol/acetaminophen (single administration) for perineal pain in the early postpartum period 2021 · Cochrane Headline outcomes only
RR 2.14 [1.59, 2.89]
10 studies · 1279 participants
Low

Paracetamol (single administration, any dose) vs placebo

Additional pain relief · women with perineal pain following childbirth

Paracetamol (single administration, any dose) may leads to lower additional pain relief compared with placebo (low certainty).

1 finding from 1 review

Paracetamol/acetaminophen (single administration) for perineal pain in the early postpartum period 2021 · Cochrane Headline outcomes only
RR 0.34 [0.21, 0.55]
8 studies · 1132 participants
Low